Antipsychotic drugs and obesity.

[1]  C. Correll,et al.  Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice , 2011, European Psychiatry.

[2]  C. Correll,et al.  Antipsychotic‐associated all‐cause and cardiac mortality: what should we worry about and how should the risk be assessed? , 2010, Acta psychiatrica Scandinavica.

[3]  S. Woods,et al.  Molecular neuroendocrine targets for obesity therapy. , 2010, Current opinion in endocrinology, diabetes, and obesity.

[4]  C. Correll,et al.  Past and present progress in the pharmacologic treatment of schizophrenia. , 2010, The Journal of clinical psychiatry.

[5]  J. Hebebrand,et al.  Association Study of Energy Homeostasis Genes and Antipsychotic-Induced Weight Gain in Patients with Schizophrenia , 2010, Pharmacopsychiatry.

[6]  A. Malhotra,et al.  DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. , 2010, Pharmacogenetics and genomics.

[7]  R. Coccurello,et al.  Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. , 2010, Pharmacology & therapeutics.

[8]  M. Maj,et al.  Endocannabinoid Pro129Thr FAAH Functional Polymorphism But Not 1359G/A CNR1 Polymorphism Is Associated With Antipsychotic-Induced Weight Gain , 2010, Journal of clinical psychopharmacology.

[9]  F. Greenway,et al.  Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men , 2010, Obesity.

[10]  R. Rosmond,et al.  Further exploration of the possible influence of polymorphisms in HTR2C and 5HTT on body weight. , 2010, Metabolism: clinical and experimental.

[11]  C. Correll,et al.  Management of antipsychotic-related weight gain , 2010, Expert review of neurotherapeutics.

[12]  W. Kaschka,et al.  Pharmacogenomics in psychiatry. , 2010, The Harvard mental health letter.

[13]  C. Correll,et al.  Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients , 2010, Neuropsychopharmacology.

[14]  S. Tsai,et al.  Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment , 2010, Pharmacogenetics and genomics.

[15]  C. Correll.  From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics , 2010, European Psychiatry.

[16]  J Brug,et al.  A systematic review of environmental factors and obesogenic dietary intakes among adults: are we getting closer to understanding obesogenic environments? , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[17]  C. Correll,et al.  Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis , 2010, Neuropsychopharmacology.

[18]  S. Yusuf,et al.  Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. , 2010, European heart journal.

[19]  Peilin Jia,et al.  Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs , 2010, Molecular Psychiatry.

[20]  Xu-Feng Huang,et al.  The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain? , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  J. Kane,et al.  Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. , 2010, The American journal of psychiatry.

[22]  J. Lieberman,et al.  A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia , 2010, Neuropsychopharmacology.

[23]  N. Wainwright,et al.  Association between serotonin 5-HT-2C receptor gene (HTR2C) polymorphisms and obesity- and mental health-related phenotypes in a large population-based cohort , 2010, International Journal of Obesity.

[24]  D. Allison,et al.  Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean? , 2009, Psychiatry Research.

[25]  S. Bloom,et al.  Obesity treatment: novel peripheral targets. , 2009, British journal of clinical pharmacology.

[26]  A. Malhotra,et al.  Pharmacogenetics of antipsychotic-induced side effects , 2009, Dialogues in clinical neuroscience.

[27]  A. Malhotra,et al.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.

[28]  H. Möller,et al.  Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) , 2009, European Psychiatry.

[29]  G. Reynolds,et al.  Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors , 2009, Psychopharmacology.

[30]  Jingping Zhao,et al.  Adiponectin gene +45T/G and +276G/T polymorphism and antipsychotic-induced weight gain. , 2009, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[31]  V. Simon,et al.  Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. , 2009, The Journal of clinical psychiatry.

[32]  J. Lieberman,et al.  Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study , 2009, Schizophrenia Research.

[33]  D. Allison,et al.  Weight effects associated with antipsychotics: A comprehensive database analysis , 2009, Schizophrenia Research.

[34]  S. Korneev,et al.  Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine , 2009, Psychopharmacology.

[35]  I. Lipkovich,et al.  Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis , 2009, BMC psychiatry.

[36]  J. Hebebrand,et al.  Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. , 2009, Journal of psychiatric research.

[37]  Paul W. Franks,et al.  Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden , 2009, Human molecular genetics.

[38]  G. Muscettola,et al.  Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  Ann E. Maloney,et al.  Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. , 2008, The American journal of psychiatry.

[40]  L. Sikich.  Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study (American Journal of Psychiatry (September 15, 2008) (1420-1431) doi:10.1176/app , 2008 .

[41]  R. McIntyre,et al.  Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. , 2008, Archives of pediatrics & adolescent medicine.

[42]  Yu-Shin Ding,et al.  Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: Possible contributing factors , 2008, NeuroImage.

[43]  J. Vázquez-Barquero,et al.  Effect of Antipsychotics on Peptides Involved in Energy Balance in Drug-Naive Psychotic Patients After 1 Year of Treatment , 2008, Journal of clinical psychopharmacology.

[44]  J. Lieberman,et al.  Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. , 2008, The Journal of clinical psychiatry.

[45]  L. Hranov,et al.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.

[46]  D. Jeste,et al.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin , 2008, Schizophrenia Research.

[47]  N. Volkow,et al.  Food restriction markedly increases dopamine D2 receptor (D2R) in a rat model of obesity as assessed with in‐vivo μPET imaging ([11C] raclopride) and in‐vitro ([3H] spiperone) autoradiography , 2008, Synapse.

[48]  J. Olié,et al.  Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review , 2007, Schizophrenia bulletin.

[49]  T. Pollmächer,et al.  Clozapine and Olanzapine Are Associated With Food Craving and Binge Eating: Results From A Randomized Double-Blind Study , 2007, Journal of clinical psychopharmacology.

[50]  J. Kennedy,et al.  Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. , 2007, The international journal of neuropsychopharmacology.

[51]  H Remschmidt,et al.  No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation , 2007, The Pharmacogenomics Journal.

[52]  M. Keshavan,et al.  Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis , 2007, Schizophrenia Research.

[53]  J. Lieberman,et al.  Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.

[54]  M. Arranz,et al.  Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research , 2007, Molecular Psychiatry.

[55]  Biao Wang,et al.  Deletion of the serotonin 2c receptor from transgenic mice overexpressing leptin does not affect their lipodystrophy but exacerbates their diet-induced obesity. , 2006, Biochemical and biophysical research communications.

[56]  Xiao-Bing Gao,et al.  Leptin Receptor Signaling in Midbrain Dopamine Neurons Regulates Feeding , 2006, Neuron.

[57]  S. Fulton,et al.  Leptin Regulation of the Mesoaccumbens Dopamine Pathway , 2006, Neuron.

[58]  R. Findling,et al.  Risperidone in the management of disruptive behavior disorders. , 2006, Journal of child and adolescent psychopharmacology.

[59]  N. Byrne,et al.  Energy Expenditure and Physical Activity in Clozapine use: Implications for Weight Management , 2006, The Australian and New Zealand journal of psychiatry.

[60]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[61]  H. Yoshimatsu,et al.  Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. , 2004, Diabetes.

[62]  A. Malhotra,et al.  Pharmacogenetics of antipsychotic-induced weight gain , 2004, Psychopharmacology.

[63]  Paul Ernsberger,et al.  H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[64]  S. Kapur,et al.  Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[65]  R. Perfetti,et al.  Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. , 2002, European journal of endocrinology.

[66]  H. Haas,et al.  The physiology of brain histamine , 2001, Progress in Neurobiology.

[67]  A. Snowman,et al.  From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. , 2007, Proceedings of the National Academy of Sciences of the United States of America.